Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial

BACKGROUND: Patients with radioactive iodine ((131)I, RAI)-refractory locally advanced or metastatic differentiated thyroid cancer (DTC) have a poor prognosis due to the lack of effective treatment options. METHODS: This multicentre, randomized (1:1), double-blind, placebo-controlled, phase 3 study...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet
Main Authors: Brose, Marcia S, Nutting, Christopher M, Jarzab, Barbara, Elisei, Rossella, Siena, Salvatore, Bastholt, Lars, de la Fouchardiere, Christelle, Pacini, Furio, Paschke, Ralf, KeeShong, Young, Sherman, Steven I, Smit, Johannes WA, Chung, John, Kappeler, Christian, Pena, Carol, Molnár, István, Schlumberger, Martin J
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4366116/
https://ncbi.nlm.nih.gov/pubmed/24768112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(14)60421-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados